IRF4 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, in RNA-interference studies, IRF4 inhibition has been demonstrated to be toxic to myeloma cell lines [35]; gene expression profiling also demonstrated IRF4 to target MYC in activated B cells, providing further evidence that aberrant IRF4 regulation is critical for B cell activation.[35] Finally, though downregulation of IRF4 expression has been reported in chronic myeloid leukemia and acute myeloid leukemia patients, IRF4 levels appear to increase during good response to IFN-alpha therapy [36].